JPMorgan Downgrades Insulet to Neutral
JPMorgan has downgraded insulin‑pump maker Insulet Corp from Overweight to Neutral, removing it from its Analyst Focus List. The brokerage reduced the price target by 45%, cutting it to $152 from the prior $275.
The firm lowered its 2027 revenue projection by 7.6% to $3.67 billion and trimmed the adjusted earnings‑per‑share estimate by 8.8% to $7.62. Changes to the 2026 outlook were modest, but the 2026 organic sales‑growth outlook was reduced due to weakness in the U.S. Type 2 diabetes segment.
JPMorgan cited a slowdown in U.S. sales growth, rising attrition among Type 2 diabetes patients, and an increasingly competitive patch‑pump market as the primary reasons for the downgrade. The bank also said management’s early 2027 commentary appeared overly optimistic and did not fully reflect continued business deceleration, competitive pressures, and reimbursement risks.
Although Insulet’s second‑quarter earnings beat expectations and profitability guidance improved, the analyst emphasized that investors are focused on the decelerating top‑line rather than margin expansion. International performance remained solid, driven by strong Omnipod adoption and recent market entries in Spain and Australia, but JPMorgan expects these positives to be outweighed by the U.S. slowdown and anticipated competition in 2027.
The brokerage concluded that investors should remain cautious until Insulet demonstrates stabilized growth and a reset of earnings expectations.